ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2015
Potential neuroprotective activity of Ginseng in Parkinson's disease: a review.
Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 100 citations in OpenAlex.
- Prophylactic efficacy of ninjin'yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2).International journal of clinical oncology · 2020Trial
- Red ginseng-mediated modulation of the NLRP3 Inflammasome in neuroinflammatory-related cognitive impairments.Journal of ginseng research · 2026Review
- NF-κB signaling pathway mediates the anti-tumor effect of Ginsenoside Rg1 in glioblastoma.Biochemistry and biophysics reports · 2026Article
- Research Progress on the Mechanism of Ginsenosides in the Treatment of Parkinson's Disease.International journal of molecular sciences · 2026Review
- Nutrients and bioactive compounds as modifiers of neurodegenerative trajectories: molecular mechanisms, translational barriers, and precision nutrition.Frontiers in nutrition · 2026Review
- Pseudoginsenoside-F11: a comprehensive review of chemical structure, pharmacological activities, pharmacokinetics, and therapeutic potential.Frontiers in pharmacology · 2026Review
- Decoding natural products for neuroprotection: Pathway networks and structural insights for drug development.Chinese herbal medicines · 2025Review
- Notoginsenoside R2 attenuates hepatic fibrosis via STAT3-dependent hepatic stellate cells senescence induction and inflammatory microenvironment suppression.Journal of ginseng research · 2025Article
- Ginsenoside Rb1 attenuates neuroflammation via activating Wnt/β-catenin signaling pathway to exert neuroprotective effect on cerebral ischemic-reperfusion injury.Frontiers in aging neuroscience · 2025Article
- Natural products in neurodegenerative diseases: recent advances and future outlook.Frontiers in pharmacology · 2025Review
- Synthesis of Novel Plant-Derived Encapsulated Radiolabeled Compounds for the Diagnosis of Parkinson's Disease and the Evaluation of Biological Effects with In Vitro/In Vivo Methods.Molecular neurobiology · 2024Article
- The necessity of eliminating the interference of panaxatriol saponins to maximize the preventive effect of panaxadiol saponins against Parkinson's disease in rats.Journal of ginseng research · 2024Article
- Therapeutic Candidates for Alzheimer's Disease: Saponins.International journal of molecular sciences · 2023Review
- Beneficial role of rosemary extract on oxidative stress-mediated neuronal apoptosis in rotenone-induced attention deficit hyperactivity disease in juvenile rat model.Acta bio-medica : Atenei Parmensis · 2023Article
- Immunomodulatory, Anti-Inflammatory, and Anti-Cancer Properties of Ginseng: A Pharmacological Update.Molecules (Basel, Switzerland) · 2023Review
- Herbal/Natural Compounds Resist Hallmarks of Brain Aging: From Molecular Mechanisms to Therapeutic Strategies.Antioxidants (Basel, Switzerland) · 2023Review
- Ginsenoside Rg1 as a promising adjuvant agent for enhancing the anti-cancer functions of granulocytes inhibited by noradrenaline.Frontiers in immunology · 2023Article
- Silibinin Protects against HAntioxidants (Basel, Switzerland) · 2022Article
- A focus on natural products for preventing and cure of mitochondrial dysfunction in Parkinson's disease.Metabolic brain disease · 2022Review
- Kurarinone alleviated Parkinson's disease via stabilization of epoxyeicosatrienoic acids in animal model.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease is a chronic, multifactorial and progressive neurologic condition that affects around six million people worldwide, normally over 60 years of age, and is characterized by neurodegeneration of dopaminergic neurons in the substantia nigra. The species of the genus Panax, popularly named as "Ginseng", are widely used as herbal remedies for their multiple beneficial effects, including their neurotherapeutic efficacies as protectors against major neurodegenerative diseases. The current review aims to report major findings and current knowledge on Ginseng and its major constituents as potential neuroprotective agents against Parkinson's disease, focusing on its mechanisms of action and molecular targets. For that purpose, it includes all research works published in MEDLINE/PubMed within the last decade by utilizing the following combination of the keywords: "Ginseng, ginsenosides, neuroprotection and Parkinson's disease". As reported, most of the studies have been carried out on isolated compounds rather than extracts. The major ginsenosides investigated as neuroprotector agents for Parkinson's disease are Rb1, Rg1, Rd and Re. Other minor components such as Notoginsenoside R2 and Pseudoginsenoside-F11 have also attracted remarkable interest as promising antiparkinson agents. These compounds exert their neuroprotective activity through different mechanisms including, among others, inhibition of oxidative stress and neuroinflammation, decrease in toxins-induced apoptosis and nigral iron levels, and regulation of N-methyl-D-aspartate receptor channel activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.